WO1999058566A1 - INHIBITION DE LA FONCTION DE p53 PAR UNE SUBSTANCE DERIVEE DE p53 - Google Patents

INHIBITION DE LA FONCTION DE p53 PAR UNE SUBSTANCE DERIVEE DE p53 Download PDF

Info

Publication number
WO1999058566A1
WO1999058566A1 PCT/SE1999/000807 SE9900807W WO9958566A1 WO 1999058566 A1 WO1999058566 A1 WO 1999058566A1 SE 9900807 W SE9900807 W SE 9900807W WO 9958566 A1 WO9958566 A1 WO 9958566A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
protein
substance
binding
dna binding
Prior art date
Application number
PCT/SE1999/000807
Other languages
English (en)
Inventor
Klas Wiman
Galina Selivanova
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to AU45394/99A priority Critical patent/AU4539499A/en
Publication of WO1999058566A1 publication Critical patent/WO1999058566A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a peptide derived from the apoptosis regu- lating protein p53 as well as to different uses thereof.
  • Apoptosis is a morphologically defined form of programmed cell death, which has very recently been seen after ischemic injury to the central ner- vous system and heart muscle and seems likely to be involved in chronic degenerative diseases like multiple sclerosis (Crowe et al., 1997).
  • a protein denoted p53 has been shown to be a key regulator of apoptosis in tissues of different types. Under normal conditions, p53 is inactive and present at a very low levels in a latent form. In cells, the p53 protein is activated and detectable only under stress conditions, such as hypoxia and DNA damage (Ko, L.J., and C. Prives. (1996) p53: "Puzzle and paradigm". Genes & Dev. 10, 1054-1072). Thus, accumulation of p53 in cells results in the induction of apoptosis or growth arrest, depending on the cell type. Therefore, the activity of the p53 protein is very tightly regulated, both through allosteric mechanisms and protein levels.
  • p53 expression is increased in damaged neurons in models of ischemia and epilepsy.
  • p53 null mice it was shown that p53 expression is required for induction of cell damage in a model of seizu- re activity (Morrison et al., (1996): “Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death", J. Neurosci. 16, 1337- 1345).
  • loss of p53 function prevents cell death in the central nervous system during embryonic development (Macleod et al., (1996): “Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 15, 6178-6188).
  • p53 is a specific DNA binding protein, which acts as a transcriptional activator of genes that control cell growth and death.
  • the ability of the p53 protein to induce apoptosis is dependent on the specific DNA binding function.
  • Mutant p53 proteins carrying amino acid substitutions in the core domain of p53, which abolish the specific DNA binding are unable to induce apoptosis in cells. Therefore, in order to obtain such substances and methods as defined above, an inhibition of p53 DNA binding is essential in order to inhibit p53- triggered apotosis in tissues during pathological conditions.
  • WO 95/19367 shows screening assays for identifying agents that affect p53- dependent expression. It is suggested that such agents are capable of interaction with p53.
  • WO 93/24525 discloses a peptide comprising an amino acid sequence derived from human p53 protein useful in prophylactic or therapeutic treatment of diseases showing p53 overexpression.
  • WO 97/14794 discloses that p53 is dependent on a C-terminal negative regulatory domain and how phosphorylation or deletion of said domain activates the DNA sequence-specific binding thereof
  • the aim of this patent is to obtain activation of latent p53 protein, and this is achieved by providing a substance, which consists of the C-terminal regulatory domain of p53 protein or a fragment of a murine p53 including the epitope bound by antibody Pab241, which according to the WO 94/12202 is used to activate mutant p53.
  • WO 95/17213 The object of WO 95/17213 is to identify the major structural domains of the human p53 protein.
  • this patent relates to a recombinant nucleic acid molecule encoding a portion of the p53 protein.
  • Said polypeptide binds specifically to DNA having the sequence specifically recognized by p53. It is also capable of activating transcription of the DNA sequences, whose transcription is activated by p53.
  • the suggested use of this polypeptide is in a method for treating a subject suffering from a neoplasm associated with the presence of mutant p53 protein.
  • the prior ait does not disclose any specific inhibitor of the apoptosis inducing activity of p53 protein.
  • the object of the present invention is to fulfill the above defined need. This is achieved by providing a substance capable of inhibiting the sequence specific DNA-binding activity of latent p53 protein, as disclosed in claim 1.
  • the substance according to the invention is used in pharmaceutical compositions intended for treatment of pateints suffering from various degenerative conditions.
  • Figure 1A-C illustrates how the peptide according to the invention inhibits the sequence specific DNA binding of the p53 protein.
  • Figure 2 discloses how the DNA binding of the constitutively activated GST-p53- ⁇ 30 fusion protein is inhibited by the peptide according to the in- vention.
  • Figure 3A-D illustrates the interaction of the peptide according to the invention with the core and C-terminal domains of p53.
  • Figure 4A-B describes how the peptide according to the invention prevents the complexing of peptide 46 with the p53 core domain.
  • Figure 5A-B are diagrams illustrating the inhibition of the transactivation function of p53 by the peptide according to the invention.
  • Peptide 14 is sometimes used to denote the peptide defined by SEQ ID NO 1 of the present application. In analogy therewith, the peptides defined by SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4 are sometimes denoted peptide 13, peptide 15 and peptide 21, respectively.
  • a “derivative” is a peptide modified by varying the amino acid sequence of the original p53 fragment. Such derivatives of the natural amino acid sequence may involve insertion, deletion or substitution of one or more amino acids, without fundamentally altering the essential activity of the peptide.
  • a “functional mimetic” means a substance which may not contain a fragment or active portion of p53 amino acid sequence, and which preferably is not a peptide, but which has some or all of the properties of the p53 fragment, in particular the property of inhibiting the specific DNA binding activity of p53 by binding thereto. More specifically, a preferred functional mimetic may be a peptidomimetic, wherein a part or all of the peptide is replaced by a structure lacking peptide bonds. Whether completely or partially non-peptide, such a functional mimetic according to the invention will provide a spatial arrangement of reactive chemical moieties that closely re-flects the three dimensional arrangement of active groups in the peptide according to the present invention. As a result of this similar active-site geometry, the functional mimetic has effects on biological systems which are similar to the biological activity of the original molecule.
  • a “functional moiety” means a non-p53 derived molecule, for example a label, a drug, or a carrier molecule.
  • label means a moiety, which has been joined, either covalently or non-covalently, to the present substance in order to provide a detectable signal.
  • label may be detected by spectro- scopic, photochemical, biochemical, immunochemical, or chemical means.
  • useful labels include P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in a ELISA), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available (e.g., the peptide of SEQ ID NO 1 can be made detectable, e.g., by incorporating a radio-label into the peptide, and used to detect antibodies specifically reactive with the peptide).
  • hybridising specifically to refers to the binding, duplexing, or hybridising of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.
  • stringent conditions refers to conditions under which a probe will hybridise to its target subsequence, but to no other sequences. Stringent conditions are sequence- dependent and will be different in different circumstances. Longer sequences hybridise specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point Tm for the specific sequence at a defined ionic strength and pH.
  • the Tm is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at Tm, 50% of the probes are occupies at equilibrium).
  • stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides).
  • Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
  • nucleic acid refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogs of natural nucleotides that can function in a similar manner as naturally occurring nucleotides.
  • antibody refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen).
  • the present invention relates to a substance capable of inhibiting the sequence specific DNA-binding activity of p53 protein.
  • the substance comprises a fragment of about 15-30, preferably about 20-25 and most preferred about 22, amino acids of the core domain of p53, or a functional mimetic of said fragment.
  • said fragment need not be identical to the sequence of the core domain of p53, but may include variations, as long as the activity thereof is preserved.
  • said fragment may also be a derivative of the p53 sequen- ce, or an active portion thereof.
  • an "active portion” means a portion of the p53 peptide which is less than the full amino acid sequence of the fragment above, but which retains the property of inhibiting the specific DNA binding activity of p53. Also it is to be understood, that in the present application, the human p53 is particularly preferred, even though p53 molecules of other origins may also be contemplated.
  • the substance according to the invention is capable of providing said inhibition of the sequence specific DNA-binding activity of latent p53 by binding to the core domains and/or C-terminal domains of p53 protein.
  • the specific domains have never been identified prior to the present invention.
  • the fragment or functional mimetic thereof is coupled to a functional moiety, which enhances the p53 in- hibiting effect of said substance.
  • a functional moiety may be any non-p53 derived molecule, for example a label, a drug, or a carrier molecule.
  • the functional moiety is a carrier molecule coupled to the present substance.
  • the functional moiety is a p53 inhibiting molecule.
  • the present substance is coupled to a label, providing a detectable signal.
  • labels and conjugation techniques are known and reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, co- factors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles and the like.
  • the present substance contains a fragment comprising a substantial part of the sequence disclosed in SEQ ID NO 1, preferably all of it.
  • SEQ ID NO 1 discloses a 22-mer peptide, which is derived from the p53 core domain and corresponds to resi- dues 105-126. This peptide is sometimes also denoted peptide 14.
  • the molecules according to the invention can be purified according to standard procedures in the art, including HPLC purification, fraction column chromatography, gel electrophoresis and the like, see generally Scopes, Protein Purification, Springer- Verlag, NY, 1982.
  • standard chemical peptide synthesis methods may be used, see e.g. Barany and Merrifield, Solid-Phase Peptide Synthesis: pp. 3-284 in The Peptides: Analysis, Synthesis, Biology. Vol.
  • WO 95/17213 relates to molecules binding to the sa- me DNA as p53 does, whereby the transcription thereof may be activated.
  • WO 95/17213 solves another problem than the present invention by use of different molecules.
  • WO 97/14794 also relates to the problem of how to activate the sequence specific DNA binding activity of latent p53. To obtain this, a fragment of the C-terminal regulatory domain of p53 is used. Thus, the function of the p53 fragments disclosed in said patent application is the opposite from the object of the present invention, which is illustrated by the use of a fragment from another domain than the p53 fragment forming the basis of the present invention.
  • a short synthetic peptide, peptide 14, derived from the p53 core domain has been identified, which can be used to inhibit the specific DNA binding function of p53.
  • the inhibition of p53 function can be achieved in living cells upon introduction of the peptide in cells by lipopfection, i.e. transfection performed with a liposomal transfer compound, such as DOTAP (Boehringer-Mannheim), LIPOFECTLN etc.
  • DOTAP Boehringer-Mannheim
  • LIPOFECTLN LIPOFECTLN
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a substance according to the invention, and as defined above, together with a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions according to the invention, and for use in accordance with the invention may comprise, in addition to one of the above substan- ces, a pharmaceutically acceptable excipient, buffer or stabilizer, or any other material well known to those skilled in the art and appropriate for the intended application. Such materials should be nontoxic and should not interfere with the efficacy of the active ingredient. Examples of techniques and protocols to this end may e.g. be found in Remington's Pharmaceutical Sciences, 16 th edition, Osol, A. (ed.), 1980.
  • composition according to the invention may be prepared for any route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular or intraperitoneal.
  • routes of administration e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular or intraperitoneal.
  • a parenterally acceptable aqueous solutions is employed, which is pyrogen free and has requisite pH, isotonicity and stability.
  • Those skilled in the art are well able to prepare suitable solutions and numerous methods are described in the literature (for a brief review of methods of drug deli- very, see Langer, Science 249: 1 527-1533 (1990)).
  • Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included, as required.
  • Dosage levels can be determined by those skilled in the art, taking into account the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.
  • composition according to invention further comprises one or more additional p53 inhibitors.
  • a third object of the present invention is the use of substance defined above as a medicament.
  • the invention relates to the use of these sub- stances as medicaments for minimizing the hypoxic tissue injury in my- ocardial infarction and stroke and for the treatment of degenerative and autoimmune disorders caused by deregulated excessive apoptosis, such as multiple sclerosis, ischemia, epilepsy, neurodegenerative diseases, anapla- sitic anemia and others. Consequently, the present invention also relates to the use of the above defined substances in the manufacture of a medicament for the treatment and/or prevention of degenerative diseases or conditions linked to enhanced deregulated apoptosis, such as the ones defined above, preferably ischemia or multiple sclerosis.
  • a fourth aspect of the present invention is a nucleic acid encoding such a fragment as the one present in the substance according to the invention.
  • the nucleic acid may e.g. be DNA or RNA.
  • the present invention also relates to a vector comprising a nucleic acid according to the invention.
  • Said vector may be a plasmid, a virus, etc, and is easily prepared by conventional methods disclosed in the literature.
  • a further aspect of the present invention is an antibody raised against the peptide 14 region of p53 or raised against peptide 14.
  • Such an antibody may be monoclonal or polyclonal. Methods for producing antibodies against specific sequences are also disclosed in the literature (see e.g. Stites et al. (eds.), Basic and Clinical Immunology (4 th ed.) Lange Medical Publications, Los Altos, CA). The antibody may be produced in a cell, which cell then is also within the scope of the present invention. Further, selection may be performed in libraries of recombinant antibodies in phage or similar vectors (see e.g. Huse et al., Science 246: 1275-1281; and Vaughan et al. (1996), Nature Biotechnology, 14:309-314).
  • Another aspect of the invention is a method of screening for compounds capable of inhibiting the sequence specific DNA-binding activity of latent p53 protein, wherein a substance according to the invention is used.
  • the present substance may be used in methods screening for: compounds having one or more of the biological activities of the substance described above or compounds which are binding to the same site on a p53 molecule.
  • the candidate compounds can be selected from a synthetic combinatorial library. Examples of screeing procedures for mimetics or binding partners include: A. immobilizing the substances on a solid support and exposing the support to a library of labelled peptides or other candidate compounds, and detecting the binding of the peptides or candidate compound to the substances; B. using the substances and a library of unlabelled candidate compound or peptides to find candidate compounds that compete or syner- gise with the substances in the inhibition of p53;
  • a further aspect of the invention is method of designing an organic compound capable of inhibiting the sequence specific DNA-binding activity of p53 protein, wherein a substance according to the invention is used as a "lead" compound.
  • the organic compound is modelled to resemble the three dimensional structure of amino acids no. 105-126 of p53 protein, i.e. the sequence of SEQ ID NO 1, or a shorter fragment of this region, which preferably exhibits substantially the same activity.
  • the designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where it is unsuitable for a particular method of administration, e.g. peptides are unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal.
  • Mimetic design, synthesis and testing are generally used to avoid randomly screening large number of molecules for a target property. There are several steps commonly taken in the design of a mimetic from a compound having a given target property. Firstly, the particular parts of the compound that are critical and/or important in determining the target property is determined.
  • the pharmacophore Once the pharmacophore has been found, its structure is modelled accor- ding to its physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources (spectroscopic techniques, X-ray diffraction data and NMR). Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this mo- delling process.
  • the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this in the design of the mimetic.
  • a template molecule is then selected onto which chemical groups that mimic the pharmacophore can be grafted.
  • the template molecule and the chemical groups grafted on to it can conventionaly be selected so that the rni- metic is easy to synthesize, is likely to be pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of the lead compound.
  • the mimetic or mimetcs found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimization or modification can be carried out to arrive at one or more final mimetics for in vivo or clinical testing.
  • the present invention also relates to methods of medical treatment wherein the substances, fragments and molecules according to the invention are used.
  • the methods may be preventive.
  • the substances and nucleic acids according to the invention may also be used in gene therapy.
  • gene therapy procedures see Anderson, Science (1992) 256:808-813; Nabel and Feigner (1993) TIBTECH 11:211-217; Mitani and Caskey (1993) TIBTECH 11: 162-166; Mulligan (1993) Science 926-932; Dillon (1993) TIBTECH 11 : 167-175; Miller (1992) Nature 357:455-460; Van Brunt (1988) Biotechnology 6(10): 1149- 1154; Vigne (1995) Restorative Neurology and Neuroscience 8: 35-36; Kremer and Perricaudet (1995) British Medical Bulletin 51(1) 31-44; Had- dada et al. (1995) in Current Topics in Microbiology and Immunology Do- erfler and B ⁇
  • Figure 1 illustrates how peptide 14 inhibit the sequence specific DNA binding of the p53 protein. More specifically, figure 1A shows how Baculovi- rus-produced p53 protein was incubated with 100 ng of synthetic p53- derived peptides and tested for binding to the 32P-labelled BC oligonucleo- tide containing a p53 consensus binding site in a band shift assay. Lane 1, DNA binding of the p53 protein alone; lane 2, activation of the p53 specific DNA binding by peptide 46, lanes 3, 4, 5, 6, and 8 - peptides 10, 11, 12, 13, and 15, respectively, do not affect DNA binding of p53. Lane 7, inhibi- tion of the specific DNA binding by peptide 14.
  • Figure IB shows the DNA binding of the GST-p53 fusion protein in the presence of activating antybo- dy PAb421 (100 ng) and peptide 14 (100 ng) was assayed as in A, and the data was quantitated using Phospholmager.
  • Lane 1 - latent GST-p53 protein do not bind DNA
  • lane 2 - PAb421 antibody activated p53 DNA bin- ding
  • lane 3 - peptide 14 inhibited the PAb421 activated DNA binding of p53
  • control peptide 10 did not affect the binding (lane 4).
  • Figure IC shows how the DNA binding of the GST-p53 fusion protein induced by peptide 46 was assayed as in Figure 1 A.
  • Peptide 46 activated the DNA binding of GST p53 in a dose dependent manner: lanes 2 - 5, 10 ng of peptide 46, lanes 6 - 10, 50 ng and lanes 10 - 13, 100 ng of peptide 46.
  • An excess of peptide 14 over peptide 46 is required in order to inhibit the DNA binding of p53: lanes 3,7, and 11 - 10 ng of peptide 14; lanes 4,8, and 12 - 50 ng of peptide 14, lanes 5, 9, and 13 - 100 ng of peptide 14.
  • Lane 1 - GST-p53 does not bind DNA in the absence of peptides.
  • Figure 2 illustrates the DNA binding of the constitutively activated GST- p53- ⁇ 30 fusion protein is inhibited by peptide 14.
  • the specific DNA binding of the GST-p53-_d30 protein was tested in a band shift assay as described in Fig. lA. Incubation of the GST-p53- l30 protein with 100 ng of pep- tide 14 prevented its sequence specific DNA binding (lane 3). Overlapping peptides 13 and 15 did not affect the DNA binding of GST-p53-_d30 (lanes 2 and 4).
  • Figure 3 illustrates the interaction of the peptide 14 with the core and C- terminal domains of p53. More specifically, figure 3 A shows the 32P- labelled peptide 14 retained on glutathione-Sepharose beads with immobilized GST-p53 proteins was analyzed by SDS polyacrylamide gel electropho- resis and autoradiography. The results of quantitation performed using Phospholmager are presented. Peptide 14 bound to the full length GST-p53 protein (1-393), column 2, and to the GST-p53 (99-307) and GST-p53 (320-393) fusion proteins, columns 4 and 5, respectively. No significant binding to the GST protein alone or to the GST-p53 (1-100) protein was observed (columns 1 and 2, respectively).
  • Figure 3B shows how native gel electrophoresis reveals complex formation between the 32P-labelled p53 (99-307) protein and peptide 14.
  • C and D the binding of the peptide 14 to the labelled C-terminal (residues 320-393) and N-te ⁇ ninal (residues 1-100) p53 polypeptides, respectively, was assayed as in B.
  • Lane 1 in C and D migration of the polypeptide in the absence of synthetic peptides, lanes 2, 3, 4, and 5 - migration of polypeptides upon incubation with synthetic peptides 10, 11, 12, 13, 14, and 15, respectively.
  • Peptide 14 altered the migration of the C-terminal polypeptide (C, lane 3).
  • Figure 4 illustrates that peptide 14 prevents the complexing of peptide 46 with the p53 core domain. More specifically, figure 4 A shows how the 32P- labelled peptide 46 was incubated with the GST-p53 protein and the pepti- de/protein complexes were separated by native polyacrylamide gel elect- rophoresis. Lane 1, labelled peptide 46 forms a complex with the GST-p53 fusion protein; lanes 2 and 3, incubation of GST-p53 protein with 100 and 200 ng of unlabelled peptide 14 inhibited the complex formation with labelled peptide 46 in a dose-dependent manner; lane 4, control peptide 10 (200 ng) did not affect peptide 46/p53 complexing.
  • Figure 4B shows how peptide 14 prevented complex formation of the GST-p53 (99-307) protein, representing the p53 core domain with peptide 46.
  • Biotinylated peptide 46 was immobilized on Streptavidin-coated Dynabeads and incubated with the GST-p53 (99-307) protein in the presence of several p53-derived peptides.
  • the protein bound to peptide 46-loaded beads was analysed by Western blotting using the p53 specific antibody PAb240.
  • Lane 1 50 ng of the GST- p53(99-307) protein; lane 2 - GST-p53(99-307) protein bound to peptide 46 in the absence of competing peptide; lane 5, in the presence of peptide 14 (50 mg) the GST- ⁇ 53(99-307) protein did not bind to peptide 46; lanes 3,4, and 6 - incubation with 50 ⁇ g of peptides 12, 13, and 15, respectively, did not affect complex formation.
  • Figure 5 illustrates the inhibition of p53 tiansactivation function of p53 by peptide 14. More specifiically, figure 5 A shows how the PG-CAT reporter construct was cotransfected into HeLa cells together with wild type p53 expression vector and 20 or 50 ⁇ g/ml of the synthetic 22-mer peptides deri- ved from the p53 core domain. Representative results from three independent experiments are shown. Column 1, transfection with empty vector. Wild type p53 caused a 10-fold increase in CAT activity (column 2). Introduction of peptide 14 resulted in complete inhibition of the transactivation function of the wild type p53 protein (lane 4, 50 ⁇ g/ml), whereas control peptide 21 did not inhibit p53 function (column 5).
  • Figure 5B shows how peptide 14 was cotransfected with PG-CAT reporter plasmid, wt p53 expression plasmid and C-terminal domain-derived peptide 46.
  • Peptide 46 caused a strong induction of wild type p53 -mediated transactivation of the CAT reporter gene in a dose dependent manner (columns 2 and 3, 5 and 20 ⁇ g/ml, respectively).
  • Introduction of 50 ⁇ g/ml of peptide 14 abolished the stimulatory activity of peptide 46 and completely inhibited p53 function (columns 4 and 5, 5 and 20 ⁇ g/ml, respectively).
  • Column 1 transfection with empty vector.
  • Plasmids The plasmids encoding the GST-human wild type p53 fusion protein and the deletion fusion proteins GST-p53( 1-100), GST-p53 (99- 307), GST-p53(320-393) and GST-p53- ⁇ 30 were described earlier (Balkalkin et al., 1995; Selivanova et al., 1996).
  • Synthetic peptides The 22-mer synthetic peptides 10-15 span residues 73- 126 of the p53 protein. Each peptide is shifted by 8 amino acid residues relative to the previous peptide.
  • Peptides were synthesized using the Merrifield solid phase method or purchased from Genosys (UK). Purification by HPLC was performed on a Super Pac pep-S column.
  • sequences of the peptides in one letter code is follows: GSYGFRLGFLHSGTAKSVTCTY (peptide 14; SEQ ID NO 1); VPSQKTYQGSYGFRLGFLHSGT (peptide 13; SEQ ID NO 2); FLHSGTAKSVTCTYSPALNKMF (peptide 15; SEQ ID NO 3) and AIYKQSQHMTEVVRRCPHHERC (peptide 21; SEQ ID NO 4).
  • Transfections and CAT assays were performed as described (Selivanova et al, 1997).
  • p53 expression vectors pC53-SN3 and pC53-SCX3 (V143A) or control vector pL15TK (0,5 ⁇ g each) were cotransfected with a CAT re- porter plasmid PG-CAT (2 ⁇ g) and ⁇ -galactosidase expression vector pRSV ⁇ gal (0,5 ⁇ g) with or without synthetic peptides (5-50 ⁇ g) using lipo- fectamine (Gibco BRL).
  • CAT activity was assayed 48 hours post transfection. The efficiency of transfection was verified by measurment of ⁇ - galactosidase activity in cell extracts.
  • Protein-protein and peptide-protein interaction assays Reactions for the peptide-protein interactions analysed in the native gel mobility assay were performed in a buffer used for the DNA binding assay and containing 2% BSA. GST-p53 proteins and peptides were labelled with 32-P- ⁇ -ATP phosphorylation by heart muscle kinase (Sigma) under the conditions described by manufacturer. Peptide-protein and protein-protein complexes were resolved on a 4% native polyacrylamide gel electrophoresis and exposed to X-ray film.
  • 32-P-labelled peptide 46 was incubated with the GST-p53 proteins (100 ng) immobilized on glutathione-Sepharose at 20°C for 30 minutes in binding buffer. After subsequent washing with binding buffer, peptides retained on the beads were eluted by boiling in a sample buffer and separated on a 15% SDS polyacrylamide gel. Quantita- tion was performed using Phosphorlmage analysis (Molecular Dynamics).
  • a panel of 22-mer overlapping synthetic peptides spanning the whole p53 protein sequence have been screened for their ability to affect the specific DNA binding activity of the full length p53 protein.
  • the binding of the baculovirus produced p53 protein to the 32- P-labelled DNA oligonucleotide containing the p53 consensus binding site was studied in band shift assays in the presence of 50 pM of synthetic peptides. Two peptides were selected that affected the specific DNA binding of p53.
  • peptide 46 spanning residues 361 to 382 of the p53 C- terminus, stimulated p53 specific DNA binding 50-100 fold, as described earlier (Selivanova et al., (1997): "Restoration of the growth suppressor function of mutant p53 by a synthetic peptide derived from the p53 C- terminal domain, Nature Med. 3, 632-639), Fig. 1A, lane 2).
  • Peptide 14 on the contrary, inhibited the specific DNA binding of p53.
  • Peptide 14 is derived from the core domain of the p53 protein and corresponds to residues 105-126.
  • peptide 14 inhibited peptide 46-stimulated DNA binding of p53 in a dose-dependent manner. An excess of peptide 14 over peptide 46 is required in order to inhibit specific DNA binding of p53.
  • the GST-p53- ⁇ 30 protein binds to DNA very efficiently, as we have shown before (Selivanova et al., (1996): "The single stranded DNA end binding site of p53 coincides with the C-terminal regulatory region", Nucl Acids Res., 24, 3560-3567), Fig. 2, lane 1). Incubation of the GST- p53- ⁇ 30 protein with peptide 14, but not the overlapping peptide 13, inhibited its constitutively activated specific DNA binding (lanes 2 and 3). Thus, peptide 14 was not only capable of inhibiting activation of p53 by PAb421 antibody or C-terminal peptide, but blocked DNA binding of the core domain in the absence of the negative regulatory domain.
  • Peptide 14 interacts with the core and C-terminal domains of the p53 pro- tein
  • Peptide 14 binds to the full length p53 protein, since it was retained on beads with immobilized GST-p53 protein, but not with GST protein alone (Fig. 3A, columns 1 and 2). Peptide 14 was also retained on beads containing the p53 proteins representing the core and C- terminal domains (columns 4 and 5), but not the N-terminal domain (column 3). Thus, peptide 14 can bind both the C-terminal and the core domains of p53.
  • peptide 14 can shift the position of the p53 core and C-terminal domains in a native gel mobility assay. Incubation of a 32-P-labelled protein representing the core domain of p53 (residues 99-307) with peptide 14 but not the overlapping peptides 13 and 15 caused a shift in protein mobility, so that the protein does not enter the gel (Fig 3B, lanes 2-5). Disappearence of the protein band on a native gel may result from the change in conformation and/or oli- gomerization state of the core domain complexed with peptide 14.
  • peptide 14 The migration of the protein corresponding to the p53 C-terminal domain (residues 320-393) in a native gel was also affected by the peptide 14 (Fig. 3C). In contrast, peptide 14 did not have any effect on the mobility of the protein corresponding to the residues 1-100 of the p53 N-terminal domain (Fig. 3D). Taken into consideration our results that peptide 14 is capable of inhibiting of DNA binding of the p53 protein with the deleted C-terminal regulatory domain, we suggest that peptide 14 blocks p53 DNA binding through the interaction with the core domain. Peptide 14/core domain complexing may result in a change of the core domain conformation and/or oligomerization state, preventing DNA binding. Alternatively, peptide 14 may block the core domain DNA binding due to steric hindrance.
  • the peptide 46 corresponding to residues 361-382 of the p53 C-terminus, binds to the core domain of p53 (Selivanova et al., submitted).
  • the GST- p53 protein and 32-P-labelled peptide 46 were incubated in the presence of non-labelled peptide 14 and the peptide/protein complexes were separated from unbound peptide on a native gel (Fig. 4).
  • 32-P-labelled peptide 46 migrated at the bottom of the native gel (lane 1).
  • peptide 14 blocked the interaction between peptide 46 and the p53 core domain.
  • Biotinylated peptide 46 immobilized on streptavidin- coated Dynabeads, efficiently precipitated the GST-p53 (100-300) protein representing the p53 core domain (Fig. 4B, lane 2 ).
  • the peptide 46/core domain binding is inhibited by peptide 14, but not by control peptides 13 and 15 (lane 4 and lanes 3 and 5, respectively).
  • Peptide 14 may compete with the core domain for binding to peptide 46.
  • the inhibition of peptide 46/core domain complexing by peptide 14 might occur due to changes in the core domain conformation and/or oligomerization state which mask the site for the peptide 46 interaction.
  • Peptide 14 blocks transactivation function of p53 in living cells Having established that peptide 14 can inhibit specific DNA binding of p53 in vitro through a direct interaction with the p 3 protein, the question whether peptide 14 can inhibit p53 function in living cells was addressed.
  • the transcriptional transactivation function of p53 in HeLa cells was examined in the presence or absence of peptide 14, using a p53 -responsive CAT reporter plasmid, PG-CAT. (Kem, S. E., J.A.Pietenpol, S.Thagaligam, A. Seymour, K.W. Kinzler, and B. Vogelstein. (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Substance qui a la propriété d'inhiber l'activité de liaison d'ADN, spécifique à des séquences, de p53, ladite substance étant basée sur le fragment du domaine central de liaison d'ADN de p53. Ladite substance s'est révélé inhiber la liaison d'ADN par p53 in vitro et la fonction de transactivation dans des cellules vivantes. La présente invention concerne encore l'utilisation de ladite substance, et le criblage de mimétiques.
PCT/SE1999/000807 1998-05-14 1999-05-12 INHIBITION DE LA FONCTION DE p53 PAR UNE SUBSTANCE DERIVEE DE p53 WO1999058566A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45394/99A AU4539499A (en) 1998-05-14 1999-05-12 Inhibition of p53 function by a p53-derived substance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801695A SE9801695D0 (sv) 1998-05-14 1998-05-14 Inhibition of p53 function by a p53-derived peptide
SE9801695-9 1998-05-14

Publications (1)

Publication Number Publication Date
WO1999058566A1 true WO1999058566A1 (fr) 1999-11-18

Family

ID=20411312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/000807 WO1999058566A1 (fr) 1998-05-14 1999-05-12 INHIBITION DE LA FONCTION DE p53 PAR UNE SUBSTANCE DERIVEE DE p53

Country Status (3)

Country Link
AU (1) AU4539499A (fr)
SE (1) SE9801695D0 (fr)
WO (1) WO1999058566A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014144A2 (fr) * 2001-08-10 2003-02-20 Medical Research Council Molecule

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024525A1 (fr) * 1992-05-26 1993-12-09 Rijksuniversiteit Leiden Peptides de la proteine p53 humaine destines a etre utilises dans des compositions induisant une reaction chez les lymphocytes t humains, et lymphocytes t cytotoxiques specifiques de la proteine p53 humaine
WO1995019367A1 (fr) * 1994-01-14 1995-07-20 La Jolla Cancer Research Foundation Dosages selectifs pour identifier des agents qui modifient l'expression de genes dependante de la proteine p53
WO1998006753A2 (fr) * 1996-08-13 1998-02-19 Trustees Of Princeton University Mutant de p53
WO1998007851A2 (fr) * 1996-08-22 1998-02-26 Bergmann Johanna E Agents permettant la detection, la prevention, et le traitement, avant apparition des symptômes, du cancer du sein chez les humains

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024525A1 (fr) * 1992-05-26 1993-12-09 Rijksuniversiteit Leiden Peptides de la proteine p53 humaine destines a etre utilises dans des compositions induisant une reaction chez les lymphocytes t humains, et lymphocytes t cytotoxiques specifiques de la proteine p53 humaine
WO1995019367A1 (fr) * 1994-01-14 1995-07-20 La Jolla Cancer Research Foundation Dosages selectifs pour identifier des agents qui modifient l'expression de genes dependante de la proteine p53
WO1998006753A2 (fr) * 1996-08-13 1998-02-19 Trustees Of Princeton University Mutant de p53
WO1998007851A2 (fr) * 1996-08-22 1998-02-26 Bergmann Johanna E Agents permettant la detection, la prevention, et le traitement, avant apparition des symptômes, du cancer du sein chez les humains

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014144A2 (fr) * 2001-08-10 2003-02-20 Medical Research Council Molecule
WO2003014144A3 (fr) * 2001-08-10 2003-11-27 Medical Res Council Molecule

Also Published As

Publication number Publication date
AU4539499A (en) 1999-11-29
SE9801695D0 (sv) 1998-05-14

Similar Documents

Publication Publication Date Title
CA2133306C (fr) Amplification du gene mdm2 dans les tumeurs humaines
US5883228A (en) Functionally active regions of signal transducer and activator of transcription
Hupp et al. Small peptides activate the latent sequence-specific DNA binding function of p53
EP0773996B1 (fr) INTERRUPTION DE LA LIAISON DE LA PROTEINE MDM2 ET p53 ET SON APPLICATION THERAPEUTIQUE
US20060115482A1 (en) Modifications of histone proteins as indicators of cell proliferation and differentiation
WO1997014794A1 (fr) ACTIVATION DE LA PROTEINE p53
US5463023A (en) Composition for inhibition of intracellular transcription
US5744313A (en) Assay employing novel protein domain which binds tyrosine phosphorylated proteins
US7303885B1 (en) Screening method for candidate drugs
EP0692488A2 (fr) Transducteurs de signal de l'interleukine 4 et tests de liaisons spécifiques
AU2001290179B2 (en) Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US7176035B2 (en) Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
AU2001290179A1 (en) Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
JP2002544522A5 (fr)
US7364870B2 (en) MK2 interacting proteins
WO2000075184A9 (fr) Modulation de taux de proteines au moyen du complexe scf
WO1999058566A1 (fr) INHIBITION DE LA FONCTION DE p53 PAR UNE SUBSTANCE DERIVEE DE p53
WO1999050280A1 (fr) Compositions et procedes permettant d'agir sur la regulation des transcriptions dependante et independante de p53 dans lesquelles le brca1 intervient comme mediateur
WO1997041433A1 (fr) METHODES ET MOYENS D'INTERRUPTION DE L'INTERACTION p53/RB
JP2002516394A (ja) Ｅ２ｆ活性を調節するためのアッセイ、方法及び手段
WO2001081587A1 (fr) Acetyl-transferase et ses utilisations
EP1684077A1 (fr) Procédé d'identification de modulateurs de protéines interagissantes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase